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This article reviews information regarding the clinical significance 
of antibodies to antigens in the blood group collections, the 
700 series of low-incidence antigens, and the 901 series of 
high-incidence antigens. Antibodies to many of the antigens in 
these groups are rarely encountered, meaning that available 
information is limited. For a few, the clinical significance—
the potential to cause reduced survival of transfused antigen-
positive red blood cells, a hemolytic transfusion reaction (e.g., 
anti-AnWj, anti-Emm), or hemolytic disease of the fetus and 
newborn (e.g., anti-Kg, anti-HJK)—has been documented. Many 
other specificities have so far been benign (e.g., anti-Csa, anti-M1). 
Immunohematology 2018;34:39–45.
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When an antibody, directed at an antigen expressed on 
red blood cells (RBCs), is present in the plasma of a patient 
who requires transfusion, the clinical significance of the 
antibody must be assessed to determine if blood lacking the 
corresponding antigen should be selected for transfusion.1 In 
general, an antibody is considered to have clinical relevance 
if it has been associated with acute or delayed hemolytic 
transfusion reactions (HTRs) or with a notable shortening in 
the survival of transfused RBCs or if it has caused hemolytic 
disease (or anemia) of the fetus and newborn (HDFN). 
Information relating to the clinical significance is based on 
previous experience with a particular antibody specificity. 
Thus, correct identification of the antibody specificity is 
essential. Although the need to identify the antibody specificity 
is obvious, at times identifying the (correct) antibody specificity 
may not be a simple task.
Antigens that are authenticated by the International 
Society of Blood Transfusion (ISBT) Working Party for Red 
Cell Immunogenetics and Blood Group Terminology fall into 
one of four classifications: blood group systems, collections, 
series of low-incidence antigens, and series of high-incidence 
antigens.2 This review summarizes relevant information about 
the clinical significance of antibodies to antigens in the ISBT 
collections (the 200 series), the 700 series of low-incidence 
antigens, and the 901 series of high-incidence antigens. In the 
interest of space, few original references are cited. The reader 
wishing for more details is referred to Daniels3 and Reid et al.4
Collections (ISBT 200 Series)
A collection consists of two or more antigens that are 
related serologically, biochemically, or genetically but that do 
not fit the criteria required for blood group system status. A 
blood group system is defined as consisting of one or more 
antigens controlled at a single gene locus or by two or more very 
closely linked homologous genes with little or no observable 
recombination between them. Table 1 shows information for 
the six currently established collections: Cost, Ii, ER, GLOB, 
“unnamed,” and MN CHO (MNS carbohydrate antigens). 
When the antigens in a collection become assigned to a system, 
the collection becomes obsolete; there are now seven obsolete 
collections: 201 (Gerbich), 202 (Cromer), 203 (Indian), 204 
(Auberger), 206 (Gregory), 211 (Wright), and 212 (Vel).2
Cost Blood Group Collection: Anti-Csa and Anti-Csb
This collection contains two antigens: Csa and Csb. Csa 
has a high prevalence as the antigen is expressed on RBCs of 
more than 98 percent of people in most populations; in black 
40 IMMUNOHEMATOLOGY, Volume 34, Number 2, 2018
populations, the prevalence is slightly lower (95%). Csb is 
polymorphic (prevalence of 34%). Only one example of anti-
Csb (an IgG antibody) has been reported; thus, there is no 
information regarding its clinical significance.
Anti-Csa is an IgG antibody that is detected by antiglobulin 
methods but has not been implicated in transfusion reactions 
or HDFN. Although not clinically significant, anti-Csa may 
cause a delay in transfusion because the specificity can 
be difficult to identify. Anti-Csa reactivity has many of the 
features of antibodies to Knops blood group antigens; indeed, 
five of the original Cost antigens are now part of the Knops 
system. The challenges of working with anti-Csa include 
that many are weakly reacting antibodies that are mostly 
found in patients with multiple antibodies. Furthermore, the 
Csa antigen has variable expression on RBCs from different 
people; thus, the reactivity pattern may be confusing. There 
appears to be a phenotypic association between Csa and Yka, 
as RBCs of approximately 12 percent of whites and 15 percent 
of blacks with the Yk(a–) phenotype are also Cs(a–). Because 
Csa is one of the antigens that is suppressed on RBCs with 
the dominant Lu(a−b−) phenotype [encoded by In(Lu)], it 
is perhaps not too surprising that anti-Csa has on occasion 
initially been misidentified as anti-AnWj. Anti-AnWj, in 
contrast to anti-Csa, is a specificity that has on occasion 
caused transfusion reactions (see later section “Anti-AnWj”). 
The typical recommendation for patients with anti-Csa is to 
use the “least incompatible” (a term that has generated much 
discussion) RBC unit(s) for transfusion.
Ii Blood Group Collection: Anti-i
Anti-i recognizes the i antigen; i is now the only antigen 
in the Ii collection because the I antigen was promoted to I 
blood group system status.5 The i antigen is on unbranched 
carbohydrate chains of repeating N-acetyllactosamine units 
on glycolipids and glycoproteins on RBCs and on proteins in 
plasma. All RBCs express some i antigen, and the expression 
is variable, with RBCs from neonates having the strongest 
expression. It follows, therefore, that all anti-i are autoantibod-
ies. In healthy people, autoanti-i is rare and primarily an IgM 
antibody weakly reactive at lower temperatures (4–10°C). In 
pathological situations, autoanti-i can have a high titer and 
a wide thermal range, react at 37°C, bind complement, and 
be IgG or a mix of IgG and IgM. Autoanti-i is pathologically 
significant in cold agglutinin syndrome and mixed-type 
autoimmune hemolytic anemia. The antibody is often found 
in plasma from patients with infectious mononucleosis or 
other lymphoproliferative disorders (e.g., Hodgkin’s disease) 
and occasionally causes hemolysis. Anti-i has been reported to 
occur in 64 percent of patients with human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS).6 
Because all RBCs express some i antigen, i– blood is not 
available for transfusion. Mostly this is not an issue, although 
acute intravascular hemolysis occurred in a patient with anti-i 
after transfusion of 2 RBC units that were compatible in the 
immediate spin crossmatch. With regard to HDFN, maternal 
autoanti-i can cross the placenta and has caused mild neonatal 
jaundice or resulted in the RBCs of the newborn to react in the 
direct antiglobulin test (DAT).
ER Blood Group Collection: Anti-Era, Anti-Erb, and 
Anti-ER3
This collection consists of two antigens of high prevalence 
(Era and ER3) and one of low prevalence (Erb). The antibodies 
directed at these antigens are rare, so information about their 
clinical significance is limited. All three specificities have been 
found to be IgG antibodies that react by antiglobulin methods.
Anti-Era has caused reduced RBC survival but no overt 
HTR. Clinical HDFN has not been reported, but anti-Era has 
been associated with neonatal RBCs being positive in the DAT. 
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Table 1. ISBT collections (200 series) and the antigens they 
contain
Collection Antigen
Number Name Symbol Number Symbol Prevalence (%)
205 Cost Cost 205001 Csa 95
205002 Csb 34
207 Ii I 207002 I *
208 Er ER 208001 Era >99
208002 Erb >1
208003 ER3 >99
209 Globoside GLOB 209003 LKE 98




213 … MN CHO 213001 Hu 7−22 1
213002 M1 16.5 0.5 
213003 Tm 31 25 
213004 Can 60 27 
213005 Sext 24 (N+) 0
213006 Sj 4 2
* All RBCs have trace amounts of i antigen, but by standard tests i may 
appear to be of low incidence.
† Anti-Lec and anti-Led react with Le(a−b−) RBCs from non-secretors and 
secretors, respectively.
ISBT = International Society of Blood Transfusion.
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The only reported patient with anti-ER3 experienced a mild 
transfusion reaction. No data are available for HDFN, since 
the only example of anti-ER3 was made by a male patient. 
Because Er(a−) or ER:−3 blood is unlikely to be found, unless 
the patient has a compatible sibling, it is recommended by some 
that “serologically least incompatible” blood should be used 
with extra caution. Only one example of anti-Erb is reported; 
therefore, its clinical significance with regard to transfusion is 
not known. This antibody has not caused clinical HDFN but 
was associated with a positive DAT.
GLOB Blood Group Collection: Anti-LKE
Anti-LKE recognizes the high-incidence antigen, LKE, 
now the only antigen in the GLOB collection. LKE is located 
on a globoside molecule that has additional galactose (Gal) 
and N-acetyl neuraminic acid residues. The expression of LKE 
on RBCs varies: 80–90 percent of people have RBCs with 
strongly expressed LKE, and 10–20 percent of people have 
RBCs with weakly expressed LKE. The LKE− phenotype is 
found in only 1–2 percent of the population. Therefore, anti-
LKE is rare; only six examples have been reported, and some 
appear to be “non–red cell immune.” They are IgM antibodies 
with optimal reactivity at room temperature or lower and 
may bind complement. One antibody was associated with 
posttransfusion hemolysis, but there have been no reports of 
HDFN. The antibody can be mistaken for anti-P as RBCs with 
the rare p, P1k, and P2k phenotypes do not react, and anti-LKE 
may be difficult to identify as RBCs typed for LKE are not 
routinely available. LKE− blood is not available for transfusion; 
thus, “serologically least incompatible” blood is given.
Unnamed Blood Group Collection: Anti-Lec and  
Anti-Led
Despite their name, the determinants recognized by these 
antibodies are not the product of transferases encoded by 
Lewis (FUT3) genes. However, like Lewis antigens, Lec and 
Led antigens are adsorbed onto RBCs. Anti-Lec reacts with 
an antigen expressed on Le(a−b−) RBCs from adult non-
secretors, whereas anti-Led reacts with an antigen expressed 
on Le(a−b−) RBCs from adult secretors. These antibodies have 
no clinical significance with regard to transfusion.
MN CHO Collection
The antigens of the MN CHO collection (Table 1) are 
expressed on glycophorin A (GPA) molecules that have altered 
levels of glycosylation in that the amount of N-acetyl neura-
minic acid or N-acetyl-D-glucosamine is different from that 
present on “conventional” GPA. Some antigens are associated 
with altered GPAN, whereas others are associated with 
altered GPAM. The antibodies that detect these determinants 
are considered to be non–red cell immune and of no clinical 
significance, but can complicate antibody identification. The 
optimal reactivity of these antibodies is at room temperature, 
and most are likely to be IgM, although available information 
is limited. For readers wishing to learn more about these 
antigens, please refer to Daniels,3 Issitt and Anstee,7 or Dahr 
et al.8
Low-Incidence Antigens (ISBT 700 Series)
Antigens in the 700 series occur with an incidence of 
less than 1 percent in most populations studied and do not 
have the criteria to be included in an established blood group 
system or collection. Inheritance of the antigen through at least 
two generations must be demonstrated for the antigen to join 
the 700 series.2 In the clinical setting, antibodies to antigens 
in the 700 series are usually found because the antibody 
has caused HDFN or a transfusion reaction if an electronic 
crossmatch was used. These antibodies may also be found 
when a patient’s serum or plasma reacts with a single RBC 
sample during compatibility testing. Before the introduction 
of monoclonal blood typing reagents, many antibodies to 
low-incidence antigens were found as contaminants in blood 
typing reagents. Currently, there are 17 antigens in the 700 
series. Some of the antibodies to these antigens are red cell 
immune, whereas others appear to be “naturally occurring” (or 
non–red cell immune). Antibodies to low-incidence antigens 
rarely cause a problem for transfusion as compatible blood is 
readily available. Several antibodies have caused HDFN, but 
this is a rare occurrence because of the low prevalence of these 
antigens that may have been identified in only one family; they 
are summarized in Table 2.
High-Incidence Antigens (ISBT 901 Series)
Antigens in the 901 series occur with an incidence of 
greater than 90 percent in most populations studied and 
cannot be included in an established blood group system or 
collection. This series was originally numbered as the 900 
series but was renumbered as the 901 series in 1988 after 
many of the antigens were relocated to systems or collections.9 
To be included in this series, it must be demonstrated that the 
antigen is lacking from the RBCs of at least two siblings (i.e., 
that the antigen-negative phenotype is genetically determined). 
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Currently, there are six antigens in the 901 series, and they are 
shown in Table 3.
Anti-Sda
Anti-Sda detects an antigen with a prevalence of about 91 
percent. The strength of Sda antigen expression is variable, 
from barely detectable, such that some RBCs may erroneously 
be considered as Sd(a−), to high levels of Sda expression 
[termed Sd(a++)] that results in non-group A1 RBCs being 
agglutinated by Dolichos lectin. Anti-Sda is easily recognized 
because it causes a characteristic mixed-field agglutination of 
orange refractile agglutinates that may look like bunches of 
grapes when viewed microscopically. Urine (human or guinea 
pig) that contains Tamm-Horsfall glycoprotein can be used to 
inhibit anti-Sda. The antibodies are mostly IgM, but some are 
IgG; they often react at lower temperatures and by antiglobulin 
methods. Although anti-Sda is not generally considered a 
transfusion hazard, and Sd(a−) RBCs are not required for 
transfusion, serologically least incompatible RBCs should be 
selected to avoid Sd(a++) RBCs.
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Table 2. Antigens and antibodies of the ISBT 700 series of low-incidence antigens
Antibody characteristics*
ISBT number Name Symbol Immune Stimulus unknown Caused HDFN† Number of antibodies found‡
700002 Batty By Yes Yes DAT+ Many
700003 Christiansen Chra … Yes No Few
700005 Biles Bi Yes … Probably Few
700006 Box Bxa … Yes … Few
700017 Torkildsen Toa … Yes … Many
700018 Peters Pta … Yes … Many
700019 Reid Rea Yes … Mild Few
700021 Jensen Jea … Yes No Few
700028 Livesay Lia Yes Yes Mild Few
700039 Milne … … Yes … Many
700040 Rasmussen RASM Yes … DAT+ 1
700044 … JFV Yes … DAT+ to moderate Few
700045 Katagiri Kg Yes … Severe† 1
700047 Jones JONES Yes … Moderate Few
700049 … HJK Yes … Severe† 1
700050 … HOFM Yes … Mild 1
700054 … REIT Yes … Severe† 1
*The antibodies in this table may occur as IgM, IgG, or a mix of both.
†Severe HDFN requiring intrauterine or exchange transfusion.
‡Few = 1–5 examples; many = >13 examples.
ISBT = International Society of Blood Transfusion; HDFN = hemolytic disease of the fetus and newborn; DAT = direct antiglobulin test.
Table 3. Antigens and antibodies of the ISBT 901 series of high-
incidence antigens
ISBT number Name Symbol Clinical significance of antibody
901008 … Emm See text
901009 Anton AnWj See text
901012 Sid Sda Not considered to be (may 
increase titer) but two suspected 
HTRs associated with RBCs with 
unusually strong expression of Sda 
[Sd(a++)] 
901014 … PEL The four makers of anti-PEL (or the 
related specificity anti-MTP) were 
transfused; three  were pregnant; 
no indication of HDFN; normal 
RBC survival with one anti-PEL 
but potential reduced survival with 
anti-MTP
901015 … ABTI No evidence of HDFN; no data for 
transfusion reactions; first three 
probands were Israeli
901016 … MAM See text
ISBT = International Society of Blood Transfusion; HTR = hemolytic 
transfusion reaction; RBCs = red blood cells; HDFN = hemolytic disease of 
the fetus and newborn.
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Anti-Emm
The Emm antigen is carried on a glycosylphos-
phatidylinositol-linked protein in the RBC membrane. Because 
the Emm− phenotype is rare, it follows that few examples of 
the antibody have been reported. IgG anti-Emm are more 
common than IgM (four out of five) and, although the original 
anti-Emm reacted in direct testing at 4°C, most of these 
antibodies react optimally by antiglobulin methods. Some 
anti-Emm have bound complement. There is no information 
regarding HDFN as six of the reported anti-Emm were found 
in untransfused males. Until 2013, anti-Emm had not been 
implicated in a transfusion reaction, possibly because the 
patients were not transfused.
In 2013, Takahashi et al.10 reported the case of a 58-year-
old man who had never been transfused but who was in 
urgent need of transfusion because of massive bleeding 
from an abdominal stab wound. Pretransfusion testing 
demonstrated an antibody that was reactive with all panel 
cells but nonreactive with the autologous RBCs. Thirty 
minutes after transfusion of a crossmatch-incompatible unit 
of blood, the patient experienced a drop in blood pressure and 
hematuria. Because his hemoglobin was 5.5 g/dL, another 
2 units of blood were transfused, and his vital signs became 
stable. A transfusion on the third day was uneventful. On day 
6, after receiving 30 mL blood, the patient vomited, had cola-
colored urine (total bilirubin 6.1 mg/dL, lactate dehydrogenase 
LDH 912 U/L), and the transfusion was stopped. No further 
transfusions were administered, and the patient recovered 
with iron therapy. After transfusion, his RBCs reacted in the 
DAT: 1+ on day 1, 2+ on day 3, and negative on day 7 (the day 
after the acute HTR occurred), suggesting that no transfused 
RBCs remained in circulation. The antibody in the patient’s 
plasma reacted in saline at 4°C (2+), by albumin–indirect 
antiglobulin test (IAT) (2+), polyethylene glycol-IAT (2+), 
and papain-IAT (3+), and was identified as anti-Emm. The 
antibody had IgG1 and IgG3 components and was shown to 
fix complement. Before transfusion, the antibody titer was 16 
by saline-IAT and rose to 128 by day 10.
Anti-AnWj
Anti-AnWj has been an intriguing specificity from the 
beginning and can at times be tricky to identify. An apparent 
alloantibody to an antigen called Anton, which was thought to 
be an antigen in the Lutheran system, was reported in 1982. 
A year later, an autoantibody called anti-Wj was reported, and 
in 1985, it was shown that both antibodies detected the same 
antigen (now named AnWj).4 The AnWj antigen is absent 
or only weakly expressed on RBCs of the dominant Lu(a−
b−) phenotype encoded by In(Lu). Lu(a–b–) dominant-type 
RBCs not only have greatly reduced expression of Lutheran 
antigens, but also of AnWj, Indian, Knops, Csa, MER2, and 
P1 blood group antigens.3.4 This antigen suppression is the 
result of heterozygosity for any one of several inactivating 
changes in KLF1, the gene that encodes erythroid Krüppel-
like factor (EKLF). These changes cause a general reduction 
of transcription of several erythroid genes and reduced levels 
of gene products such as the Lu glycoprotein. Therefore, if a 
patient’s plasma does not react with RBCs of the dominant 
Lu(a−b−) phenotype, it cannot be assumed that the reactivity 
is directed at a Lutheran antigen. Furthermore, antibody 
identification may also be complicated by the fact that the level 
of suppression on dominant-type Lu(a−b−) RBCs varies so 
that some RBC samples may react weakly with some examples 
of anti-AnWj.
Antibodies with AnWj specificity are predominantly 
autoantibodies but may appear as an alloantibody because 
of transient (often long-term) suppression of AnWj on the 
RBCs of the antibody maker. The antibody is frequently 
found in association with lymphoma (Hodgkin’s and non-
Hodgkin’s) and other lymphoid malignancies, immunologic 
disorders, and autoimmune hemolytic anemia. The only two 
reported examples of alloanti-AnWj were found in two Arab 
Israeli sisters with a history of multiple pregnancies but no 
transfusions.11 Anti-AnWj has not been associated with 
HDFN, however. The fact that pregnancy appeared to be the 
immunizing event for the sisters is somewhat puzzling, since 
fetal cells express almost no AnWj antigen and RBCs from 
cord samples type AnWj−.
Some patients with anti-AnWj tolerate “random” units,12 
whereas others do not and require blood with the dominant 
Lu(a−b−) phenotype. The antibody has been implicated in 
severe HTRs, and its hemolytic potential was substantiated by 
monocyte monolayer assay (MMA) or in vivo RBC survival 
studies.3,13 Xu et al.,14 in an informative review article, described 
the case of a 56-year-old woman with aplastic anemia with 
anti-AnWj identified in her plasma. Transfusion of “random” 
units resulted in an acute HTR. The anti-AnWj activated 
complement, and only C3 was detected on the patient’s RBCs 
when tested in the DAT. Blood from donors with the dominant 
Lu(a−b−) phenotype was well tolerated. There is a limited 
supply of blood with this rare phenotype, however, and long-
term provision can be difficult, if not impossible. Similar to 
the case described by Xu et al.,14 a patient with anti-AnWj and 
a diagnosis of acute myeloid leukemia was transfused with 
ISBT collections, 700 series, 901 series
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a “random” unit, matched for common antigens. About 100 
mL was transfused before the procedure was stopped. The 
patient suffered from an HTR, and a follow-up MMA at a later 
date showed that the anti-AnWj was expected to be clinically 
significant. The patient’s RBCs, when tested in the DAT, were 
coated with C3 only, and an eluate prepared from the RBCs 
was nonreactive. Attempts to reduce the anti-AnWj production 
by giving rituximab were not successful in this case.
Because dominant type Lu(a−b−) donors are rare, it is 
important to determine if a patient with anti-AnWj can or 
cannot tolerate blood that is not AnWj−. The tiny amount 
of AnWj on dominant type Lu(a−b−) RBCs does not appear 
to affect RBC survival. RBCs with the very rare recessive or 
X-linked Lu(a−b−) phenotypes fully express AnWj and should 
not be used for patients with anti-AnWj (in the unlikely event 
that these rare types are available).4
Anti-MAM
Anti-MAM is an extremely rare antibody, and the 
MAM antigen has a high incidence (greater than 99%) in 
all populations. The antibody was first reported in 199315 
and assigned to the 901 series of high-incidence antigens in 
1999. MAM antigen is expressed on cord RBCs, lymphocytes, 
granulocytes, monocytes, and probably on platelets.
Four of the five reported examples of anti-MAM were 
identified during pregnancy in mothers who had never been 
transfused. One of the mothers was of Irish and Cherokee 
descent, and the four other antibody makers were all of Arab 
descent. The anti-MAM were IgG antibodies; antibodies from 
two patients were subtyped as IgG1 and IgG3, and one also 
had an IgG2 component. Anti-MAM has been associated with 
clinical HDFN and/or thrombocytopenia. Of the four babies 
born to mothers with anti-MAM, the course of each pregnancy 
was slightly different, although the RBCs of the newborns all 
were reactive in the DAT. One baby had no clinical HDFN 
but experienced fetal and neonatal thrombocytopenia and 
required platelet transfusion. Another had severe HDFN and 
required intrauterine RBC transfusion. In addition, this baby 
presented with fetal and neonatal thrombocytopenia, but 
platelet transfusion was not required. A third baby had mild 
HDFN requiring ultraviolet phototherapy because of elevated 
bilirubin levels but no fetal or neonatal thrombocytopenia. 
A fourth baby required no RBC transfusion, platelets, or 
phototherapy. The platelet count of the fourth baby was slightly 
reduced (132,000/µL [normal range 150,000–450,000/µL]), 
but by 8 weeks of age, the count had increased to 305,000/µL.16
With regard to transfusion, the results of the MMA suggest 
that anti-MAM has the potential to substantially reduce the 
survival of transfused MAM+ RBCs.17,18 Ideally, MAM− RBCs 
should be transfused, but, because of their extreme rarity, 
cautious transfusion of serologically “least incompatible” RBCs 
may be the only option.
Conclusions
The antibodies made to some antigens in the ISBT blood 
group collections, 700 series, and 901 series have established 
and documented clinical significance, either for transfusion 
or for HDFN, but for others the information is limited. When 
antigen-negative blood is not available and information 
regarding the clinical significance of an antibody is lacking, it 
is best to proceed with caution, since any antibody reactive by 
IAT may have clinical potential. At the same time, the risk of 
not transfusing versus a potential transfusion reaction must 
be considered, since a patient is more likely to die from lack of 
blood than from a transfusion reaction. Clinical significance 
is mostly based on previous experience with a particular 
specificity. Thus, to predict clinical significance, the antibody 
specificity must be correctly identified. At times, this can 
be a challenge. In vitro tests such as the MMA may also be 
informative.
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